CKD进展与死亡风险中的性别相关生物标志物差异
结果显示男性肾衰竭与全因死亡风险更高(HR 1.28及1.29),校正生物标志物差异后风险关联消失,提示性别差异有生物学基础。
要点
- 男性CKD患者肾衰竭与死亡风险高于女性,校正人口学、临床及治疗因素后仍存在。
- 男性炎症与细胞外基质沉积标志物较高,女性基质周转与降解标志物较高。
- 校正生物标志物差异后,男性超额风险消失,提示生物学机制解释性别差异。
核心结论
- 男性性别与CKD患者肾衰竭和全因死亡风险升高相关,校正人口学、临床和治疗因素后仍存在。
- 校正性别间生物标志物差异后,男性性别与肾衰竭和死亡的超额风险关联不再显著。
研究设计与样本
- 前瞻性多中心队列研究NURTuRE-CKD,纳入1680例男性与1204例女性非透析依赖CKD患者及84例对照。
主要发现
- 校正人口学、肾功能、合并症、社会因素和药物后,男性肾衰竭风险HR 1.28(95%CI 1.09-1.50),死亡风险HR 1.29(95%CI 1.05-1.60)。
- 男性CKD患者尿胶原1型α1、血KIM-1、GDF-15和NT-proBNP水平较高;女性CKD患者尿骨激活素、KIM-1、MMP-9和血FGF-23水平较高。
- 校正生物标志物差异后,男性肾衰竭HR 1.18(95%CI 0.97-1.43),死亡HR 1.17(95%CI 0.98-1.58),关联不再显著。
临床怎么用
- 临床中应关注男性CKD患者更高的肾衰竭和死亡风险,并考虑炎症及心血管应激生物标志物的性别差异。
- 生物标志物谱可能有助于解释性别间预后差异,但尚需进一步验证用于风险分层。
局限性
- 研究为观察性设计,不能确立因果关系。
- 生物标志物校正后风险关联消失提示生物学介导,但具体机制未完全阐明。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
KEY POINTS: A higher risk of kidney failure and mortality persisted in men with CKD, despite adjusting for sociodemographic, clinical, and treatment factors. Differences in biomarkers linked to CKD progression and cardiovascular stress were observed between men and women after adjusting for eGFR and urine albumin-to-creatinine ratio. When adjusting for the differences in the biomarkers, the excess risk of kidney failure and mortality seen in men was eliminated. BACKGROUND: Men with CKD experience worse outcomes than women, a difference not fully explained by comorbidities or sociocultural factors. We explored whether sex-based differences in biomarkers could account for this difference in risk. METHODS: Our study included 1680 male and 1204 female participants with non-dialysis-dependent CKD and 84 controls from National Unified Renal Translational Research Enterprise-CKD, a prospective multicenter cohort study. Twenty-one biomarkers relating to kidney injury and fibrosis, inflammation, and cardiovascular stress were measured. Outcomes were kidney failure (eGFR <15 ml/min per 1.73 m 2 or kidney replacement therapy) and all-cause mortality. Multivariable Cox and Fine and Gray models assessed outcomes by sex. Analysis of covariance compared biomarker values between men and women adjusted for eGFR and urine albumin-to-creatinine ratio. RESULTS: Sex differences in biomarker concentrations were observed in both controls and CKD participants. In male controls, higher levels of urinary vascular endothelial growth factor, tissue inhibitor of metalloproteinases-1 and blood neutrophil gelatinase-associated lipocalin, soluble cluster of differentiation 40, soluble cluster of differentiation 40 ligand, soluble tumor necrosis factor receptor 1, monocyte chemoattractant protein-1, and high-sensitivity cardiac troponin T were observed. In men with CKD, additionally higher levels of urine collagen type 1 α 1, blood kidney injury molecule-1, Growth Differentiation Factor-15, and N -terminal pro-B-type natriuretic peptide were noted, while women with CKD showed higher urinary osteoactivin, kidney injury molecule-1, Matrix Metalloproteinase-9, and blood Fibroblast Growth Factor-23 concentrations. In Cox proportional hazards models adjusted for demographics, kidney function, comorbidities, social factors, and medications, male sex was associated with a higher risk of kidney failure (hazard ratio [HR] 1.28; 95% confidence interval, 1.09 to 1.50) and mortality (HR, 1.29; 95% CI, 1.05 to 1.60). Male sex was no longer associated with higher risk after adjustment for biomarker differences, kidney failure (HR, 1.18; 95% CI, 0.97 to 1.43), and mortality (HR, 1.17; 95% CI, 0.98 to 1.58). CONCLUSIONS: Male sex was associated with a higher risk of kidney failure and mortality, despite adjustment for demographic, clinical, and treatment factors. Men had higher levels of inflammatory and extracellular matrix deposition biomarkers. By contrast, women showed higher levels of matrix turnover and degradation markers. After adjustment for these biomarker differences, the elevated risk associated with male sex was eliminated, suggesting a biologic basis for the observed sex difference in outcomes. CLINICAL TRIAL REGISTRY NAME AND REGISTRATION NUMBER: NCT04084145 .
引用
- McDonnell T, Onoja A, Vuilleumier N, et al. Sex-Associated Biomarker Differences in CKD Progression and Mortality. Clin J Am Soc Nephrol. 2026. PMID: 41642662. doi:10.2215/CJN.0000000979
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。